Kintor Pharmaceutical
| File:Kinter Logo.svg | |
| Public | |
| Traded as | |
| ISIN | 🆔 |
| Industry | |
| Founded 📆 | 2009 in Suzhou |
| Founder 👔 | |
| Headquarters 🏙️ | No. 20 Songbei Road, Suzhou , China |
Area served 🗺️ | |
Key people | Youzhi Tong |
| Products 📟 | Pharmaceuticals |
| Members | |
Number of employees | |
| 🌐 Website | en |
| 📇 Address | |
| 📞 telephone | |
Kintor Pharmaceutical is a Chinese pharmaceutical company founded in 2009 that focuses on developing novel innovative small molecules and biologic drugs for androgen-related diseases.
Its primary drug candidate is proxalutamide, which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The company is also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib, and an inhibitor of the hedgehog signal translation pathway GT1708F.
See also
References
 | This Chinese corporation or company article is a stub. You can help EverybodyWiki by expanding it. |
| Stub icon | This China-related article is a stub. You can help EverybodyWiki by expanding it. |
This article "Kintor Pharmaceutical" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Kintor Pharmaceutical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
